Exact Sciences Corporation ( together with its subsidiaries, " Exact, " " we, " " us, " " our" or the " Company" ) is a molecular diagnostics company currently focused on the early detection and prevention. Selling in shares of Exact Sciences continued after the stock topped $ 60.Strong Cologuard ordering may justify high valuation. Roughly 18 months ago, Exact Sciences ( NASDAQ: EXAS) was in rough shape.
Is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. EXAS has developed, and currently commercializes the Cologuard test, a non- invasive stool- based deoxyribonucleic acid screening test designed to detect DNA markers for colorectal cancer.
EXACT Sciences Corp. Stay up to date with real time EXAS stock quotes, historical charts and the latest financial news and investing data for Exact Sciences Corp.
Oct 03, · Updated Stock chart for EXACT Sciences Corp. Dive deeper with interactive charts and top stories of Exact Sciences Corp.
Through our partnership with Mayo Clinic to discover the most relevant biomarkers and Exact Sciences’ technology platforms, we can extract trace amounts of the most relevant DNA, and use a combination of biomarker types to help detect cancer and pre- cancer at its earliest, most treatable stages. And hear what the experts at.
Price target: $ 61. Exact Sciences Corporation ( EXAS) Pre- Market Trading - View free premarket stock trades at NASDAQ.
EXACT Sciences Corp.